Why will it never be known if convalescent plasma is effective for COVID-19

High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion crit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas, Manuel, Anaya, Juan-Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641519/
https://www.ncbi.nlm.nih.gov/pubmed/33169114
http://dx.doi.org/10.1016/j.jtauto.2020.100069
_version_ 1783605931883364352
author Rojas, Manuel
Anaya, Juan-Manuel
author_facet Rojas, Manuel
Anaya, Juan-Manuel
author_sort Rojas, Manuel
collection PubMed
description High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.
format Online
Article
Text
id pubmed-7641519
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-76415192020-11-05 Why will it never be known if convalescent plasma is effective for COVID-19 Rojas, Manuel Anaya, Juan-Manuel J Transl Autoimmun Review article High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19. Elsevier 2020-11-04 /pmc/articles/PMC7641519/ /pubmed/33169114 http://dx.doi.org/10.1016/j.jtauto.2020.100069 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review article
Rojas, Manuel
Anaya, Juan-Manuel
Why will it never be known if convalescent plasma is effective for COVID-19
title Why will it never be known if convalescent plasma is effective for COVID-19
title_full Why will it never be known if convalescent plasma is effective for COVID-19
title_fullStr Why will it never be known if convalescent plasma is effective for COVID-19
title_full_unstemmed Why will it never be known if convalescent plasma is effective for COVID-19
title_short Why will it never be known if convalescent plasma is effective for COVID-19
title_sort why will it never be known if convalescent plasma is effective for covid-19
topic Review article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641519/
https://www.ncbi.nlm.nih.gov/pubmed/33169114
http://dx.doi.org/10.1016/j.jtauto.2020.100069
work_keys_str_mv AT rojasmanuel whywillitneverbeknownifconvalescentplasmaiseffectiveforcovid19
AT anayajuanmanuel whywillitneverbeknownifconvalescentplasmaiseffectiveforcovid19

Ejemplares similares